Attached files
| file | filename |
|---|---|
| EX-10.7 - EX-10.7 - Apellis Pharmaceuticals, Inc. | d445089dex107.htm |
| EX-10.6 - EX-10.6 - Apellis Pharmaceuticals, Inc. | d445089dex106.htm |
| EX-10.5 - EX-10.5 - Apellis Pharmaceuticals, Inc. | d445089dex105.htm |
| EX-4.1 - EX-4.1 - Apellis Pharmaceuticals, Inc. | d445089dex41.htm |
| EX-3.4 - EX-3.4 - Apellis Pharmaceuticals, Inc. | d445089dex34.htm |
| EX-3.3 - EX-3.3 - Apellis Pharmaceuticals, Inc. | d445089dex33.htm |
| S-1/A - S-1/A - Apellis Pharmaceuticals, Inc. | d445089ds1a.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated October 4, 2017, in Amendment No. 2 to the Registration Statement (Form S-1 No. 333-220941) and related Prospectus of Apellis Pharmaceuticals, Inc. dated October 27, 2017.
/s/ Ernst & Young LLP
Louisville, KY
October 27, 2017